Ernesto Ernesto Moro-Rodriguez

Dr. Ernesto Ernesto Moro-Rodriguez

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1995 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
CVCarlos Navarro Vila
Carlos Navarro Vila
CMCarlos Martínez‐Gimeno
Carlos Martínez‐Gimeno
EMErnesto Ernesto Moro-Rodriguez
Ernesto Ernesto Moro-Rodriguez
CVCarmen Lopez Varela
Carmen Lopez Varela

20 January 2008 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
EME. G. Marazuela
E. G. Marazuela
NPN. Prado
N. Prado
EMErnesto Ernesto Moro-Rodriguez
Ernesto Ernesto Moro-Rodriguez
HFH. Fernández‐García
H. Fernández‐García
MVMayte Villalba
Mayte Villalba
EBE. Batanero
E. Batanero

29 January 2004 in Proteomics
Verified
Journal Article
Closed access
PDF file
PAPatricia Alfonso
Patricia Alfonso
MCMyriam Catalá
Myriam Catalá
MRMaría Luisa Rico‐Morales
María Luisa Rico‐Morales
Gonzalo Durante-RodriguezGonzalo Durante-Rodriguez
Gonzalo Durante-Rodriguez
EMErnesto Ernesto Moro-Rodriguez
Ernesto Ernesto Moro-Rodriguez
EGEduardo García‐Poblete
Eduardo García‐Poblete

9 September 2009 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
BGBenjamín García-Espinosa
Benjamín García-Espinosa
MNM. Paz Nieto-Bona
M. Paz Nieto-Bona
SRSonsoles Rueda
Sonsoles Rueda
LSLuís Fernando Silva-Sánchez
Luís Fernando Silva-Sánchez
MPMa Concepción Piernas-Morales
Ma Concepción Piernas-Morales
EMErnesto Ernesto Moro-Rodriguez
Ernesto Ernesto Moro-Rodriguez
Background: The HVP vaccine is a useful tool for preventing cervical cancer. The purpose of this study is to determine the most frequent HPV genotypes in Equatorial Guinea in order to develop future vaccination strategies to apply in this country. Methods: A campaign against cervical cancer was carried out in the area on a total of 1,680 women. 26 of the women, following cytological screening, were treated surgically with a loop electrosurgical excision procedure (LEEP). Cases were studied histologically and were genotyped from paraffin blocks by applying a commercial kit that recognized 35 HPV types. Results: Cytological diagnoses included 17 HSIL, 1 LSIL, 5 ASC-H and 3 AGUS. Histological diagnosis resulted in 3 cases of microinvasive squamous cell carcinoma stage IA of FIGO, 9 CIN-3, 8 CIN-2, 2 CIN-1, 3 flat condylomas and mild dysplasia of the endocervical epithelium. Fifteen of twenty-five cases genotyped were positive for HPV (60%). HPV 16 and 33 were identified in four cases each, HPV 58 in two other cases, and HPV 18, 31, 52, and 82 in one case, with one HPV 16 and 58 coinfection. Conclusion: The frequency of HPV types in the African area varies in comparison to other regions, particularly in Europe and USA. Vaccination against the five most common HPV types (16, 33, 58, 18, and 31) should be considered in the geographic region of West Africa and specifically in Equatorial Guinea.

20 November 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
BGBenjamín García-Espinosa
Benjamín García-Espinosa
EMErnesto Ernesto Moro-Rodriguez
Ernesto Ernesto Moro-Rodriguez
EÁEmilio Álvarez-Fernández
Emilio Álvarez-Fernández
Background: Human Papillomavirus (HPV) genotype distribution and co-infection occurrence was studied in cervical specimens from the city of Madrid (Spain), as a contribution to the knowledge of Human Papillomavirus genotype distribution and prevalence of carcinogenic HPV types in cervical lesions in Spain. Methods: A total of 533 abnormal specimens, from the Hospital General Universitario “Gregorio Marañón” of Madrid, were studied. These included 19 benign lesions, 349 cervical intraepithelial neoplasias 1 (CIN1), 158 CIN2-3 and 7 invasive cervical carcinomas (ICC). HPV genotyping was performed using PCR and tube array hybridization. Results: We detected 20 different HPV types: 13 carcinogenic high-risk HPV types (HR-HPVs), 2 probably carcinogenic high-risk HPV types (PHR-HPVs) and 5 carcinogenic low-risk HPV types (LR-HPVs). The most frequent HPV genotypes found in all specimens were HPV16 (26.0%), 31 (10.7%) and 58 (8.0%). HPV 18 was only detected in 5.0%. Co-infections were found in 30.7% of CIN 1 and 18.4% cases of CIN2-3. The highest percentage of HR HPVs was found in those specimens with a CIN2-3 lesion (93.7%). Conclusion: As our study shows the current tetravalent vaccine could be effective in our geographical area for preventing all the invasive cervical carcinomas. In addition, upon the estimates of the important presence of other HR-HPV types – such as 31, 58, 33 and 52 – in different preneoplasic lesions the effectiveness of HPV vaccination in our geographical area, and others with similar genotype distribution, should be limited.

10 December 2013 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
BGBenjamín García-Espinosa
Benjamín García-Espinosa
EMErnesto Ernesto Moro-Rodriguez
Ernesto Ernesto Moro-Rodriguez
EÁEmilio Álvarez-Fernández
Emilio Álvarez-Fernández
We studied anal specimens to determine the distribution of human papillomavirus (HPV) genotypes and co-infection occurrence. This information will contribute to the knowledge of HPV genotype distributions and provide an estimate of the prevalence of different oncogenic HPV genotypes found in patients in Madrid (Spain).